Streetbeat News

Products Services

WBX

Wallbox (NYSE:WBX) and Bidirectional Energy have been selected by the California Energy Commission (CEC) for proposed awards of $2.2M to deploy V2X chargers across California. The partnership will offer Wallbox's Quasar 2 bidirectional charger with the Bidirectional Energy EV charger management platform. The chargers will be deployed in California residential homes, offering potential savings on utility bills and resilience during power outages. If successful, additional funding will be made available for further deployment.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 12:20 pm

PBLA

Panbela Therapeutics, Inc. (NASDAQ:PBLA) has announced the publication of preclinical and clinical data from studies of CPP-1X (DFMO) in recent onset type 1 diabetes (T1D). The data suggests that DFMO treatment may preserve β cell function and health in T1D. The research is part of a multi-site clinical trial led by Indiana University (IU) School of Medicine, supported by funding from JDRF. Panbela Therapeutics is providing the drug at no cost to researchers and was not involved in the design and analysis of these studies.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 12:18 pm

QGEN

Qiagen and Element Biosciences have announced a strategic partnership to offer comprehensive next-generation sequencing workflows for the AVITI system, a sequencing platform based on Element's novel avidity sequencing chemistry.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 12:14 pm

IMAB

I-Mab and HI-Bio have announced that the FDA has granted Breakthrough Therapy Designation for Felzartamab for the treatment of primary membranous nephropathy. This could potentially expedite the development and review process for the drug.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 12:13 pm

VXRT

Vaxart has begun dosing the first subject in a Phase 1 trial of its Norovirus vaccine candidate in lactating mothers. This marks a significant step in the development of the vaccine.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 12:12 pm

RGLS

Regulus Therapeutics has announced the dosing of the first patient in the third cohort of the Phase 1B MAD study of RGSL8429 for Autosomal Dominant Polycystic Kidney Disease.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 12:12 pm

CLRB

Cellectar Biosciences is set to release top-line data from its Waldenstrom's Macroglobulinemia (WM) pivotal trial during the JP Morgan Healthcare Conference.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 12:11 pm

OCUP

Ocuphire Pharma has announced a successful end-of-Phase 2 meeting with the FDA for oral APX3330 in Diabetic Retinopathy. The company and the FDA have agreed on the Phase 3 primary endpoint.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 12:10 pm

AMGN

Amgen has presented new data for its drug Krystexxa (Pegloticase) at the American Society Of Nephrology Kidney Week. The data shows a decrease in blood pressure during treatment in chronic gout refractory patients to oral urate-lowering treatment, both with and without chronic kidney disease.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 12:07 pm

TOVX

Theriva Biologics and Sant Joan de Déu-Barcelona Children's Hospital are advancing their strategic collaboration to explore the combination of VCN-01 with topoisomerase inhibitors for cancer treatment.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 12:06 pm